Evidence map›Paper›PMID 41126372›Full record

ArticleExperimental hematology & oncology2025

Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice.

Tao Wang, Ping Liu, Dongliang Zhang, Zhiqiang Song, Mingyang Yu, Dongge Feng, Xuejun Yu, Na Liu, Gusheng Tang, Jianmin Yang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tao Wang *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
Ping Liu *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
Dongliang Zhang *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
Zhiqiang SongDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China.
Mingyang YuDepartment of Joint Bone Disease Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Dongge FengHuadao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
Xuejun YuHuadao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
Na LiuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China. liuna2015@sibs.ac.cn.
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China. drake015@163.com.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433, China. chyangjianmin@163.com.

Funding

China Postdoctoral Science Foundation GZC20233559Medical-enterprise Integration Innovation and Collaboration Project SHDC2023CRT005National Natural Science Foundation of China 82270202National Natural Science Foundation of China (NSFC) Youth Program 82100162Research Fund for the Basic Medical Research for the youth of Naval Medical University 2024QN024Research Fund for the Basic Medical Research for the youth of the Changhai Hospital 2023QD24Shanghai Science and Technology Development Funds 23YF1458800
6 · The paper itself

Abstract

Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hematopoietic stem cells (HSCs) using a lentiviral vector. Chimeric antigen receptor-modified HSC (CAR-HSCs) were transplanted into mice after lethal irradiation. CAR gene transduction did not compromise the ability of HSCs to expand, self-renew, or reconstitute. CAR was expressed on T cells, natural killer cells, B cells, monocytes, and neutrophils in the peripheral blood. CAR-HSCs transplantation significantly reduced CD19

Indexed as

Chimeric antigen receptorHematopoietic stem cellTransplantationTumorTumor microenvironment

Identifiers

PMID41126372
PMCPMC12548230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.